製薬企業の研究開発機能における企業合併・統合効果の発現様式--アステラス製薬の事例

概要

論文の詳細を見る
In this study we investigated the effect of corporate merger and acquisition (M&A) on the uptake and diffusion of innovation in pharmaceutical research and development (R&D) from the viewpoint of corporate organization management. Here we selected a case of Astellas Pharma and observed its post-merger management (PMM) effects on the size of R&D, research efficiency and licensing efficiency for two years after the establishment. Through a series of in-depth internal interviews and analyses we found a significant diversification of technological opportunities created by the complementary effects of the M&A which may lead to inconsistent gains in research and licensing efficiencies. We also observed a considerable fit between these effects and the corporate vision and strategy that the management had initially intended. Precedent studies indicated that the positive effect of M&A tends to be limited to short-term impacts such as fulfillment of pipeline candidates. Our study suggests the significance of PMM and monitoring approaches from the economy of scope rather than the economy of scale for long-lasting effects on pharmaceutical R&D.
医療科学研究所の論文